- Home
- MIRA vs CLDI Comparison
MIRA vs CLDI Comparison
Compare MIRA & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- CLDI
- Stock Information
- Founded
- MIRA 2020
- CLDI 2014
- Country
- MIRA United States
- CLDI United States
- Employees
- MIRA N/A
- CLDI N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MIRA Health Care
- CLDI Health Care
- Exchange
- MIRA Nasdaq
- CLDI Nasdaq
- Market Cap
- MIRA 20.5M
- CLDI 22.3M
- IPO Year
- MIRA 2023
- CLDI N/A
- Fundamental
- Price
- MIRA $0.95
- CLDI $0.58
- Analyst Decision
- MIRA Strong Buy
- CLDI Strong Buy
- Analyst Count
- MIRA 2
- CLDI 2
- Target Price
- MIRA $14.00
- CLDI $15.00
- AVG Volume (30 Days)
- MIRA 360.9K
- CLDI 366.6K
- Earning Date
- MIRA 05-12-2025
- CLDI 05-13-2025
- Dividend Yield
- MIRA N/A
- CLDI N/A
- EPS Growth
- MIRA N/A
- CLDI N/A
- EPS
- MIRA N/A
- CLDI N/A
- Revenue
- MIRA N/A
- CLDI N/A
- Revenue This Year
- MIRA N/A
- CLDI N/A
- Revenue Next Year
- MIRA N/A
- CLDI N/A
- P/E Ratio
- MIRA N/A
- CLDI N/A
- Revenue Growth
- MIRA N/A
- CLDI N/A
- 52 Week Low
- MIRA $0.51
- CLDI $0.53
- 52 Week High
- MIRA $5.01
- CLDI $8.30
- Technical
- Relative Strength Index (RSI)
- MIRA 38.16
- CLDI 33.04
- Support Level
- MIRA $1.06
- CLDI $0.53
- Resistance Level
- MIRA $1.29
- CLDI $0.79
- Average True Range (ATR)
- MIRA 0.11
- CLDI 0.06
- MACD
- MIRA -0.02
- CLDI -0.01
- Stochastic Oscillator
- MIRA 4.74
- CLDI 14.57
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.